Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $4.19 Average PT from Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD) has earned an average rating of “Moderate Buy” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $4.1875.

Several research analysts recently issued reports on the stock. Weiss Ratings lowered shares of Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, July 20th. Ascendiant Capital Markets upped their price objective on shares of Lucid Diagnostics from $9.00 to $9.25 and gave the stock a “buy” rating in a report on Monday, June 8th. BTIG Research reaffirmed a “buy” rating and set a $2.50 target price on shares of Lucid Diagnostics in a research note on Friday, May 15th. Wall Street Zen lowered shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Finally, Maxim Group lowered their target price on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating for the company in a report on Friday, May 15th.

Lucid Diagnostics Price Performance

NASDAQ LUCD opened at $0.87 on Monday. The firm has a market capitalization of $177.00 million, a PE ratio of -1.85 and a beta of 1.08. The stock’s 50 day moving average is $1.01 and its 200 day moving average is $1.14. Lucid Diagnostics has a twelve month low of $0.86 and a twelve month high of $1.63.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.38 million. On average, research analysts anticipate that Lucid Diagnostics will post -0.23 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Dennis Matheis acquired 245,000 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $1.00 per share, for a total transaction of $245,000.00. Following the completion of the purchase, the director owned 1,033,443 shares of the company’s stock, valued at $1,033,443. This represents a 31.07% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lucid Diagnostics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Centiva Capital LP purchased a new stake in Lucid Diagnostics during the 3rd quarter valued at about $25,000. Abel Hall LLC purchased a new position in Lucid Diagnostics in the fourth quarter worth about $33,000. JPMorgan Chase & Co. raised its holdings in Lucid Diagnostics by 71,026.1% in the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock worth $38,000 after buying an additional 32,672 shares during the last quarter. Pine Valley Investments Ltd Liability Co lifted its stake in shares of Lucid Diagnostics by 73.2% in the first quarter. Pine Valley Investments Ltd Liability Co now owns 34,283 shares of the company’s stock worth $39,000 after buying an additional 14,487 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Lucid Diagnostics in the first quarter worth approximately $39,000. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.